272 related articles for article (PubMed ID: 36538852)
1. KLHL21/CYLD signaling confers aggressiveness in bladder cancer through inactivating NF-κB signaling.
Yuan H; Wei S; Ren Z; Li F; Liu B; Liu R; Zhang X
Int Immunopharmacol; 2023 Jan; 114():109202. PubMed ID: 36538852
[TBL] [Abstract][Full Text] [Related]
2. miR-130b, an onco-miRNA in bladder cancer, is directly regulated by NF-κB and sustains NF-κB activation by decreasing Cylindromatosis expression.
Cui X; Kong C; Zhu Y; Zeng Y; Zhang Z; Liu X; Zhan B; Piao C; Jiang Z
Oncotarget; 2016 Jul; 7(30):48547-48561. PubMed ID: 27391066
[TBL] [Abstract][Full Text] [Related]
3. Kelch-like Protein 21 (KLHL21) Targets IκB Kinase-β to Regulate Nuclear Factor κ-Light Chain Enhancer of Activated B Cells (NF-κB) Signaling Negatively.
Mei ZZ; Chen XY; Hu SW; Wang N; Ou XL; Wang J; Luo HH; Liu J; Jiang Y
J Biol Chem; 2016 Aug; 291(35):18176-89. PubMed ID: 27387502
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of m
Wang J; Tan L; Jia B; Yu X; Yao R; OUYang N; Yu X; Cao X; Tong J; Chen T; Chen R; Li J
Int J Biol Sci; 2021; 17(10):2633-2651. PubMed ID: 34326699
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
[TBL] [Abstract][Full Text] [Related]
6. Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression.
Li C; Li R; Hu X; Zhou G; Jiang G
Breast Cancer Res Treat; 2022 Apr; 192(2):353-368. PubMed ID: 35084622
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of CYLD downregulation in breast cancer.
Hayashi M; Jono H; Shinriki S; Nakamura T; Guo J; Sueta A; Tomiguchi M; Fujiwara S; Yamamoto-Ibusuki M; Murakami K; Yamashita S; Yamamoto Y; Li JD; Iwase H; Ando Y
Breast Cancer Res Treat; 2014 Feb; 143(3):447-57. PubMed ID: 24398777
[TBL] [Abstract][Full Text] [Related]
8. CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-κB activation.
Zhang LM; Zhou JJ; Luo CL
Arthritis Res Ther; 2018 Oct; 20(1):219. PubMed ID: 30285829
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of LEF1 Impairs Myeloma Cell Growth Through Modulating CYLD/NF-κB Signaling.
Zhang G; Miao F; Liu K; Wu J; Xu J
Technol Cancer Res Treat; 2021; 20():15330338211034270. PubMed ID: 34269120
[TBL] [Abstract][Full Text] [Related]
10. The E3 ubiquitin ligase MIB2 enhances inflammation by degrading the deubiquitinating enzyme CYLD.
Uematsu A; Kido K; Takahashi H; Takahashi C; Yanagihara Y; Saeki N; Yoshida S; Maekawa M; Honda M; Kai T; Shimizu K; Higashiyama S; Imai Y; Tokunaga F; Sawasaki T
J Biol Chem; 2019 Sep; 294(38):14135-14148. PubMed ID: 31366726
[TBL] [Abstract][Full Text] [Related]
11. A pro-inflammatory role of deubiquitinating enzyme cylindromatosis (CYLD) in vascular smooth muscle cells.
Liu S; Lv J; Han L; Ichikawa T; Wang W; Li S; Wang XL; Tang D; Cui T
Biochem Biophys Res Commun; 2012 Mar; 420(1):78-83. PubMed ID: 22406061
[TBL] [Abstract][Full Text] [Related]
12. MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas.
Minderman M; Lantermans HC; Grüneberg LJ; Cillessen SAGM; Bende RJ; van Noesel CJM; Kersten MJ; Pals ST; Spaargaren M
Blood Cancer J; 2023 Mar; 13(1):37. PubMed ID: 36922488
[TBL] [Abstract][Full Text] [Related]
13. Subquinocin, a small molecule inhibitor of CYLD and USP-family deubiquitinating enzymes, promotes NF-κB signaling.
Yamanaka S; Sato Y; Oikawa D; Goto E; Fukai S; Tokunaga F; Takahashi H; Sawasaki T
Biochem Biophys Res Commun; 2020 Mar; 524(1):1-7. PubMed ID: 31898971
[TBL] [Abstract][Full Text] [Related]
14. Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.
Suenaga N; Kuramitsu M; Komure K; Kanemaru A; Takano K; Ozeki K; Nishimura Y; Yoshida R; Nakayama H; Shinriki S; Saito H; Jono H
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635163
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-370-3p shuttled by breast cancer cell-derived extracellular vesicles induces fibroblast activation through the CYLD/Nf-κB axis to promote breast cancer progression.
Ren Z; Lv M; Yu Q; Bao J; Lou K; Li X
FASEB J; 2021 Mar; 35(3):e21383. PubMed ID: 33629796
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling.
Xia JT; Chen LZ; Jian WH; Wang KB; Yang YZ; He WL; He YL; Chen D; Li W
J Transl Med; 2014 Feb; 12():33. PubMed ID: 24495516
[TBL] [Abstract][Full Text] [Related]
17. CYLD expression in dendritic cells involved in the immunoregulation of pulmonary adenocarcinoma via NF-κB pathway.
Yu Q; Lei Y; Huang Y; Zhang J; Chen Y; Chen K; Lin J; Sun S; Lin X
Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):137-142. PubMed ID: 31852310
[TBL] [Abstract][Full Text] [Related]
18. RIPK4 promotes bladder urothelial carcinoma cell aggressiveness by upregulating VEGF-A through the NF-κB pathway.
Liu JY; Zeng QH; Cao PG; Xie D; Chen X; Yang F; He LY; Dai YB; Li JJ; Liu XM; Zeng HL; Zhu YX; Gong L; Cheng Y; Zhou JD; Hu J; Bo H; Xu ZZ; Cao K
Br J Cancer; 2018 Jun; 118(12):1617-1627. PubMed ID: 29867225
[TBL] [Abstract][Full Text] [Related]
19. miR-130b regulates B cell proliferation via CYLD-mediated NF-κB signaling.
Wu M; Zhao J; Wu W; Hao C; Yang Y; Zhang J
Exp Cell Res; 2024 Jan; 434(1):113870. PubMed ID: 38049082
[TBL] [Abstract][Full Text] [Related]
20. CYLD Inhibits the Development of Skin Squamous Cell Tumors in Immunocompetent Mice.
Alameda JP; García-García VA; López S; Hernando A; Page A; Navarro M; Moreno-Maldonado R; Paramio JM; Ramírez Á; García-Fernández RA; Casanova ML
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
